Thomas Martin, MD
Associate Editor
Dr. Martin is Clinical Research Director of Hematologic Malignancies at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
Articles by Thomas Martin, MD
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
The Blood Cancers Today Editorial Board reflects on the latest news in the field so far in 2023.
Dr. Martin discusses key updates in multiple myeloma from ASCO, EHA, and the IMWG meetings.
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
The panel discusses side effect management with CAR T-cell therapy.
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
The panel addresses the potential for frontline CAR-T use.
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
BCMA-targeted autologous CAR T-cell therapies are discussed.
The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.
Drs. Voorhees and Martin discuss one of the FDA-approved CAR-T therapies for myeloma, idecabtagene vicleucel.
In the first segment of the roundtable series, the panel discusses BCMA as an important target for treating multiple myeloma.
We will all experience burnout at some point, and we all need to seek more personalized ways to cope.
Thomas G. Martin, MD, and Saad Z. Usmani, MD, MBA, FACP, debate CAR-T vs bispecific antibodies for R/R MM.
As 2022 came to a close, the Blood Cancers Today Editorial Board shared their highlights from the year.
Thomas Martin, MD, discusses advances in frontline treatments for multiple myeloma, the need for novel agents, and more.
We are entering the great era of immunotherapy in multiple myeloma.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.